Active Filters
- Press ReleaseClear filter
![S1616 results at AACR 2022](/sites/default/files/styles/news_recent/public/news/2022-04/press-release-web-graphic-S1616_0.png?itok=uxB1tHGG)
Apr 8, 2022
Reversing resistance to PD-1 inhibitors with combination immunotherapy in patients with advanced melanoma
![S1314 at GU ASCO](/sites/default/files/styles/news_recent/public/news/2022-02/press-release-web-graphic-Flaig-S1314-GU-ASCO-2022_0.png?itok=9rrfByfW)
Feb 15, 2022
Survival data from the first prospective, randomized biomarker validation trial in muscle-invasive bladder cancer presented at GU ASCO
![Sex differences in risk of SAEs](/sites/default/files/styles/news_recent/public/news/2022-02/press-release-web-graphic-Unger-sex-diffs-SAEs.png?itok=sz1ThvmM)
Feb 14, 2022
Higher toxicity risk for women was known for chemotherapy, now also identified for immunotherapy and targeted therapy
![Results of S1417CD](/sites/default/files/styles/news_recent/public/news/2022-01/press-release-web-graphic-S1417CD_0.png?itok=QMiIMMgB)
Jan 4, 2022
Major financial hardship common after cancer diagnosis, despite insurance
![Anjali Advani, MD](/sites/default/files/styles/news_recent/public/news/2021-12/Advani-S1318.png?itok=we9lNwTn)
Dec 13, 2021
Combo with immunotherapy drug can be effective in patients who are not good candidates for chemo
![Megan Othus, PhD](/sites/default/files/styles/news_recent/public/news/2021-12/Othus-ASH21_1.png?itok=4786w4lf)
Dec 11, 2021
Analyses presented at ASH 2021 find statistical models can predict risk of early death with non-intensive AML therapy
![Corey W. Speers, MD, PhD](/sites/default/files/styles/news_recent/public/news/2021-12/press-release-web-graphic-Speers-SABCS21.png?itok=-Hv7EEjH)
Dec 9, 2021
Results at SABCS show assay has prognostic value that complements value of recurrence score in postmenopausal patients
![RxPONDER Trial Results: Kevin Kalinsky, MD](/sites/default/files/styles/news_recent/public/news/2021-12/KalinskyWeb-NEJM.jpg?itok=S-OhxKfp)
Dec 1, 2021
RxPONDER finds postmenopausal women with HR+, HER2- breast cancer with 1-3 involved nodes and an RS of 25 or less can safely skip chemo
![ESMO Congress 2021](/sites/default/files/styles/news_recent/public/news/2021-09/esmo-congress-2021_0.png?itok=_fFeHeRo)
Sep 20, 2021
Forty years of publicly funded trials added 14 million years of life for cancer patients and profoundly affected cancer care guidelines